{
    "id": 26412,
    "fullName": "ABL1 V468F",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ABL1 V468F lies within the protein kinase domain of the Abl1 protein (UniProt.org). V468F has been demonstrated to confer resistance to allosteric Abl1 inhibitors (PMID: 28329763, PMID: 27890928) and results in increased kinase activity and transformation in cultured cells (PMID: 27890928).",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11532,
                    "pubMedId": 27890928,
                    "title": "Identification and characterization of activating ABL1 1b kinase mutations: impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27890928"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 25,
        "geneSymbol": "ABL1",
        "terms": [
            "ABL1",
            "ABL",
            "BCR-ABL",
            "bcr/abl",
            "c-ABL",
            "c-ABL1",
            "CHDSKM",
            "JTK7",
            "p150",
            "v-abl"
        ]
    },
    "variant": "V468F",
    "createDate": "04/19/2017",
    "updateDate": "09/06/2018",
    "referenceTranscriptCoordinates": {
        "id": 119238,
        "transcript": "NM_005157",
        "gDna": "chr9:g.130878546G>T",
        "cDna": "c.1402G>T",
        "protein": "p.V468F",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10580,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) inhibited growth of transformed cells over expressing ABL1 V468F in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27628,
                "profileName": "BCR - ABL1 ABL1 V468F"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19170,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 V468F in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 27628,
                "profileName": "BCR - ABL1 ABL1 V468F"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10609,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing ABL1 V468F in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27628,
                "profileName": "BCR - ABL1 ABL1 V468F"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19169,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 V468F in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 27628,
                "profileName": "BCR - ABL1 ABL1 V468F"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19154,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing BCR-ABL1 with ABL1 V468F demonstrated resistance to Asciminib (ABL001) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 27628,
                "profileName": "BCR - ABL1 ABL1 V468F"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10585,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ABL1 V468F in the context of BCR-ABL1 were resistant to Asciminib (ABL001) in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27628,
                "profileName": "BCR - ABL1 ABL1 V468F"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10615,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing ABL1 V468F in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27628,
                "profileName": "BCR - ABL1 ABL1 V468F"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19171,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 V468F in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 27628,
                "profileName": "BCR - ABL1 ABL1 V468F"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10621,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABL1 V468F in the context of BCR-ABL1 was identified in chronic myeloid leukemia cells that acquired resistance to Asciminib (ABL001) in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27628,
                "profileName": "BCR - ABL1 ABL1 V468F"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27626,
            "profileName": "ABL1 V468F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27628,
            "profileName": "BCR - ABL1 ABL1 V468F",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 119238,
            "transcript": "NM_005157",
            "gDna": "chr9:g.130878546G>T",
            "cDna": "c.1402G>T",
            "protein": "p.V468F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}